Previous 10 | Next 10 |
Global Blood Therapeutics (NASDAQ: GBT ): Q4 GAAP EPS of -$0.93 misses by $0.04. More news on: Global Blood Therapeutics, Earnings news and commentary, Healthcare stocks news, Read more ...
SOUTH SAN FRANCISCO, Calif., Feb. 27, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today reported recent business progress and financial results for the fourth quarter and year ended December 31, 2018. “Last year was successful for GBT as ...
SOUTH SAN FRANCISCO, Calif., Feb. 21, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that it will present at the 8th Annual SVB Leerink Global Healthcare Conference in New York on Thursday, February 28, 2019, at 1 p.m. Eastern Time. The prese...
—The Access to Excellent Care for Sickle Cell Patients Pilot Program (ACCEL) Supports Novel Projects Aimed at Improving Access to High-Quality Healthcare for People with Sickle Cell Disease— —GBT Will Fund Proposals With the Highest Potential to Impact Patient Car...
Biotech Pulse Biotech tumbled off a steep ski slope in the last quarter, and at the December low, the Nasdaq Biotechnology Index ( IBB ) had declined -28%, while the S&P Biotech Select Index ( XBI ) a whopping -36%. But it seems biotechs were able to regain their composure at the lows an...
"Waste your money and you're only out of money, but waste your time and you've lost a part of your life." - Michael LeBoeuf It has been awhile since we looked in on the progress of developmental concern Global Blood Therapeutics ( GBT ) . A Biotech Forum member requested we revisit this n...
SOUTH SAN FRANCISCO, Calif. , Jan. 29, 2019 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that data from its Phase 1/2 study of voxelotor in patients with sickle cell disease (SCD) were published online in Blood , a peer-reviewed publication o...
Investment Update Investors of Global Blood Therapeutics ( GBT ) have a lot to look forward to in 2019 and beyond: Management still intends to meet with the FDA in Q1 '19 to discuss details surrounding Voxelotor's path to the market and the confirmatory trial requirements. Voxelotor'...
CRISPR Therapeutics (NASDAQ: CRSP ) is off 7% premarket on light volume on the heels of a downgrade to Sell with a $21 (43% downside risk) price target at Citigroup. More news on: CRISPR Therapeutics, bluebird bio, Inc., Global Blood Therapeutics, Healthcare stocks news, Stocks...
(Source: Evil Speculator) Anyone thinking 2018 investing hasn’t been anything other than a proverbial roller-coaster ride needs their sanity checked. Thankfully, the end of the year is fast approaching, and if given the option to choose - bull or bear - I would have, and did, opt for ...
News, Short Squeeze, Breakout and More Instantly...
Global Blood Therapeutics Inc. Company Name:
GBT Stock Symbol:
NASDAQ Market:
Global Blood Therapeutics Inc. Website:
Guerbet to Spotlight the Novel New Drug Elucirem™ (gadopiclenol) injection at the 2022 Radiological Society of North America Scientific Assembly and Annual Meeting PR Newswire Join us at Booth #1711 Opportunity to learn about the recently US FDA-approved nov...
The healthcare industry is growing at an unprecedented rate, and healthcare stocks are poised to benefit from this growth. This is large because healthcare companies are developing innovative new treatments and technologies that are transforming the way we care for our health. As a resu...
NEW YORK, NY / ACCESSWIRE / September 22, 2022 / New York, New York-Halper Sadeh LLC, an investor rights law firm, is investigating the following companies for potential violations of the federal securities laws and/or breaches of fiduciary duties to shareholders relating to: EVO Payments...